Patients with chronic severe alopecia areata, alopecia totalis, or alopecia universalis Diphenylcyclopropenone, DCP, anthralin, chronic extensive alopecia areata, alopecia universalis
Conditions
Interventions
In each patient, one side of the scalp was treated with combined DCP solution and 0.5% anthralin for 6 months. Clinical response was assessed at baseline and then monthly until the end of the 6-month
Experimental Drug,Experimental Drug
Topical diphenylcyclopropenone plus topical 0.5% anthralin ,topical diphenylcyclopropenone alone
Sponsors
Siriraj research fund , Faculty of Medicine Siriraj Hospital , Mahidol University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. patients aged equal to or more than 18 years 2. patients with chronic severe alopecia areata, alopecia totalis, or alopecia universalis
Exclusion criteria
Exclusion criteria: Patients who had other active skin disease at the scalp, who received systemic immunosuppressive or corticosteroid treatment within the past 6 months, and/or who had history of resistance to DCP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the efficacy of combination therapy of topical DCP and topical 0.5% anthralin versus topical DCP alone for the treatment of chronic extensive AA. Baseline, 1, 2, 3, 4, 5, 6 months Severity of Alopecia Tool (SALT) scores | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety Baseline, 1, 2, 3, 4, 5, 6 months Adverse events | — |
Countries
Thailand
Contacts
Public ContactDaranporn Triwongwaranat
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed